The conversation discusses the storage and use of pyrilutamide for hair loss, where one user advises against keeping it in the freezer as it may crystallize the active compounds.
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
The conversation is about the lack of discussion on Low-level laser light therapy (LLLT) laser caps for hair loss. One user questions their effectiveness, and another asserts they don't work.
The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.
The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.
A user with stage 1 hair loss is inquiring about the release date of GT20029, hoping to use it instead of Minoxidil and finasteride, as they believe it has better results. They want to know if it will be available in the next couple of years.
The conversation is about disappointment with pyrilutamide's performance as a hair loss treatment, with some users expressing interest in other treatments like Verteporfin, GT20029, and RU58841, while others suggest sticking with established treatments like finasteride or dutasteride.
A group buy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.
The user is using finasteride and minoxidil for hair loss but is looking for new treatments. Pyrilutamide and GT20029 are potential future treatments, with Pyrilutamide expected next year and GT20029 possibly by 2027.
PP405 is considered a potential new treatment for hair loss, compared to finasteride and minoxidil. There is skepticism about its effectiveness in humans, with anticipation for more information from an upcoming conference.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
The conversation discusses the availability of Breezula, a drug for hair loss, now being sold as an acne treatment, and whether it can be applied to the scalp. Users express skepticism about new hair loss treatments and suggest waiting for FDA approval.
Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.
The conversation is a satirical expression of frustration over hair loss, mentioning treatments like spironolactone, microneedling, and topical applications, with references to various hair loss products and personalities in the community.
Pyrilutamide (KX-826) is discussed as an anti-androgen treatment for hair loss, with mixed user experiences. Some users report no results, while others find it mildly effective.
Follicium XR™ is a topical treatment for hair loss containing RU58841, AHK-Cu, GHK-Cu Peptide, caffeine, D-Biotin, methylene blue, keratin, and spermidine. RU58841 is considered the most effective ingredient, but concerns exist about its stability in water.
Minoxidil works by opening potassium channels, leading to reduced blood pressure and potential side effects like reflex tachycardia. It is used for hair growth and affects blood pressure at high doses.
Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.
A user experienced excessive hair shedding after taking 17 mg of Zinc gluconate daily for acne. They are seeking advice on similar experiences and solutions.
Quercetin might help with hair loss by inhibiting HSP-70, which increases androgen receptors. Concerns include its staining properties and unclear topical absorption.
The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.
Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
A user experienced significant swelling after a hair and beard transplant, possibly due to an allergic reaction or improper post-surgery care. Despite dissatisfaction with the clinic's handling of grafts and customer service, the user appreciates the clinic's skill in achieving natural hairline density.